briumvi

The new year is bringing a new disease-modifying therapy (DMT) to the multiple sclerosis (MS) arsenal. Shortly after Christmas, the U.S. Food and Drug Administration (FDA) approved Briumvi (ublituximab), which joins a small group of DMTs that aim to halt MS progression by knocking out certain…

The U.S. Food and Drug Administration has approved TG Therapeutics‘ B-cell-depleting therapy ublituximab under the brand name Briumvi for the treatment of adults with relapsing forms of multiple sclerosis (MS), the company announced. The approval covers clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive…

Rituximab, an investigational B-cell depletion therapy that target CD20 to treat people with multiple sclerosis (MS), has significant effects on the characteristics of B-cells that return after treatment is stopped, with cells being less mature yet more activated toward a pro-inflammatory state, a study showed. Treatment also…

Immune B-cells are more abundant and have a pro-inflammatory profile in the cerebrospinal fluid (CSF), the fluid that bathes the central nervous system,  compared to blood in people with relapsing-remitting multiple sclerosis (RRMS), a study reports. The results suggest that therapeutic strategies targeting the CSF B-cells could constitute a…

The loss of immune B-cells, and the resulting changes in the profile of immune T-cells, is a major mechanism of action for the beneficial effects seen with ublituximab treatment in multiple sclerosis (MS) patients, a study suggests. B-cells are a type of immune cell best known for producing…

This year’s John Dystel Prize for Multiple Sclerosis Research is being awarded to Anne H. Cross, a neurologist and MS chair in the department of neuroimmunology at  Washington University School of Medicine in St. Louis, for her research into the role of immune B-cells in multiple sclerosis attacks and new imaging…

Appropriate control of immune B-cell numbers and activation in the nervous system is key to preventing inflammation in multiple sclerosis (MS), according to a study. These findings also showed that patients with higher levels of a specific B-cell-regulating cell type had less disease activity. The study, “…

A new and potentially important mechanism in the development of autoimmune diseases like multiple sclerosis was discovered by scientists at the University of Freiburg, Germany. They identify a protein, called Caveolin-1, that is essential to immune cells called B-cells working as intended to protect a person from pathogens or — in its absence…

A recent study published in the journal Science Translational Medicine provided new insights into the role of B cells in multiple sclerosis (MS), and points to a specific line of possible new therapies. The study is entitled “Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell…